Literature DB >> 2451274

Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3.

P Garred1, T E Mollnes, T Lea.   

Abstract

A sensitive double antibody enzyme-linked immunosorbent assay (ELISA) for quantification of C3 activation products in human plasma, synovial fluid, and cerebrospinal fluid is described. The monoclonal antibody MoAb bH6, which is specific for a C3 neoepitope expressed on C3b, iC3b, and C3c, was used as capture antibody. Detection antibody was a polyclonal rabbit anti-human C3c followed by development with a peroxidase-conjugated anti-rabbit Ig antiserum. The activity in normal human EDTA plasma was 1.5% of that in zymosan-activated serum (ZAS). The interassay and intra-assay coefficients of variation were 15% and 3%, respectively. The lower detection limit was 0.0005% of the ZAS standard. Reference range (1.1-2.1% of ZAS) was obtained by measuring EDTA plasma from 40 healthy blood donors. A positive correlation rs = +0.92; P less than 0.0002) was found between the present assay and an already established C3'g' activation ELISA, when samples from 16 patients were examined in both assays simultaneously. The present assay and an assay detecting the terminal complement complex showed virtually identical activation patterns in consecutively drawn samples from a patient undergoing extracorporal circulation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451274     DOI: 10.1111/j.1365-3083.1988.tb02354.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  23 in total

1.  The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation.

Authors:  M Harboe; G Ulvund; L Vien; M Fung; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

2.  S protein binds to serum-treated agarose beads independently of complement activation and the formation of the terminal complement complex on the beads.

Authors:  G Hetland; P Garred; H B Pettersen; T E Mollnes; E Johnson
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

Review 3.  Universal pathogen-reduced plasma in elective open-heart surgery and liver resection.

Authors:  Bjarte G Solheim
Journal:  Clin Med Res       Date:  2006-09

4.  Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials.

Authors:  T E Mollnes; V Videm; J Riesenfeld; P Garred; J L Svennevig; E Fosse; K Hogasen; M Harboe
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

5.  Activation of complement during apheresis.

Authors:  G Hetland; T E Mollnes; P Garred
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

6.  Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation.

Authors:  T E Mollnes; P Garred; G Bergseth
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

7.  Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality.

Authors:  C Homann; K Varming; K Høgåsen; T E Mollnes; N Graudal; A C Thomsen; P Garred
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

8.  Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.

Authors:  M Fung; M Lu; H Fure; W Sun; C Sun; N Y Shi; Y Dou; J Su; X Swanson; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

9.  Role for complement in development of Helicobacter-induced gastritis in interleukin-10-deficient mice.

Authors:  Hanan F Ismail; Juan Zhang; Richard G Lynch; Yi Wang; Daniel J Berg
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

10.  Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA).

Authors:  J Feuillard; F Maillet; P Goldschmidt; L Weiss; M D Kazatchkine
Journal:  Agents Actions       Date:  1991-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.